ARCA BIOPHARMA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.58 USD | +2.87% |
|
+5.29% | +110.59% |
| Apr. 25 | ARCA biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Apr. 19 | North American Morning Briefing : Stock Futures -2- | DJ |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 4.644 | 9.103 | 37.38 | 30.98 | 34.15 | 24.5 |
| Enterprise Value (EV) 1 | -1.964 | 0.7653 | -11.24 | -21.89 | -7.91 | -12.65 |
| P/E ratio | -0.58 x | -1.38 x | -1.94 x | -1.55 x | -3.44 x | -4.59 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - |
| EV / EBITDA | 0.24 x | -0.13 x | 1.15 x | 1.13 x | 0.81 x | 1.78 x |
| EV / FCF | 0.35 x | -0.24 x | 2.65 x | 1.85 x | 1.11 x | 3.06 x |
| FCF Yield | 290% | -424% | 37.7% | 53.9% | 90.3% | 32.7% |
| Price to Book | 0.77 x | 1.2 x | 0.82 x | 0.61 x | 0.82 x | 0.67 x |
| Nbr of stocks (in thousands) | 774 | 1,594 | 9,321 | 14,410 | 14,410 | 14,410 |
| Reference price 2 | 6.003 | 5.711 | 4.010 | 2.150 | 2.370 | 1.700 |
| Announcement Date | 2/27/19 | 2/18/20 | 3/18/21 | 3/14/22 | 2/24/23 | 2/1/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales | - | - | - | - | - | - |
| EBITDA 1 | -8.096 | -5.796 | -9.758 | -19.32 | -9.821 | -7.122 |
| EBIT 1 | -8.118 | -5.814 | -9.766 | -19.34 | -9.841 | -7.137 |
| Operating Margin | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -7.964 | -5.649 | -9.747 | -19.32 | -9.926 | -5.339 |
| Net income 1 | -7.933 | -5.482 | -9.738 | -19.32 | -9.926 | -5.339 |
| Net margin | - | - | - | - | - | - |
| EPS 2 | -10.31 | -4.149 | -2.067 | -1.390 | -0.6888 | -0.3704 |
| Free Cash Flow 1 | -5.687 | -3.242 | -4.24 | -11.81 | -7.144 | -4.142 |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 2/27/19 | 2/18/20 | 3/18/21 | 3/14/22 | 2/24/23 | 2/1/24 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 6.61 | 8.34 | 48.6 | 52.9 | 42.1 | 37.2 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -5.69 | -3.24 | -4.24 | -11.8 | -7.14 | -4.14 |
| ROE (net income / shareholders' equity) | -97.3% | -80.4% | -36% | -39.6% | -21.4% | -13.6% |
| ROA (Net income/ Total Assets) | -52.9% | -47.3% | -20.7% | -22.9% | -12.6% | -11% |
| Assets 1 | 15 | 11.59 | 47.04 | 84.23 | 79.08 | 48.44 |
| Book Value Per Share 2 | 7.800 | 4.770 | 4.870 | 3.540 | 2.890 | 2.550 |
| Cash Flow per Share 2 | 8.540 | 5.250 | 5.140 | 3.700 | 2.950 | 2.580 |
| Capex 1 | 0 | 0 | 0.02 | 0.04 | 0 | - |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 2/27/19 | 2/18/20 | 3/18/21 | 3/14/22 | 2/24/23 | 2/1/24 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +110.59% | 51.91M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- ABIO Stock
- Financials ARCA biopharma, Inc.
